Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myelodysplastic Syndromes • Internal Medicine • Hematology
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How would you sequence these therapies given approval for both?
Answer from: Medical Oncologist at Community Practice
In the past 18 months, between the COMMANDS trial looking at Luspatercept in expanded indications beyond just patients with MDS-RS and the IMerge trial looking at the use of Imetelstat in patients with low-risk MDS, we now have many more options for these patients.The COMMANDS trial looked at Luspat...
Sign in or Register to read more